Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy (GO)

Graves' Ophthalmopathy Clinical Trial

Official title:
A Phase 2a, Multicenter, Open-Label Study of RVT-1401 for the Treatment of Patients With Moderate to Severe Active Graves' Ophthalmopathy

Status Completed

Clinical Trial Summary

The purpose of this study was to evaluate safety, tolerability, and pharmacodynamic parameters of RVT-1401 in graves' ophthalmopathy (GO) patients.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT03922321
Study type	Interventional
Source	Immunovant Sciences GmbH
Contact
Status	Completed
Phase	Phase 2
Start date	April 22, 2019
Completion date	May 21, 2020

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT02059655` - Prostaglandin F2-alpha Eye Drops in Thyroid Eye Disease (Bima Study)	Phase 4
Completed	`NCT02721992` - Graves' Orbitopathy and Hypercholesterolemia	N/A
Recruiting	`NCT02290704` - Retinal Oxygen Saturation in Patients With Graves' Ophthalmopathy and in Normal People	N/A
Recruiting	`NCT01969019` - A Prospective, Randomized Trial of Intravenous Pulse Versus Sequential Steroid Therapy for Patients With Graves' Orbitopathy	Phase 4
Recruiting	`NCT01056419` - The Effect of Early Total Thyroidectomy in the Course of Graves' Orbitopathy	Phase 4
Completed	`NCT00697528` - Color Doppler Imaging of Orbital Venous Flow in Grave's Orbitopathy	N/A
Recruiting	`NCT00174057` - The Role of TSH Receptor, PPAR-r, IGF-1R, IGF and Cytokines in Different Stages of Graves’Ophthalmopathy	N/A
Completed	`NCT00430547` - Thyroid-Associated Ophthalmopathy Subtypes and Orbital Antibodies	N/A